What is NDC 81607-019?

81607-019 is the product NDC for liraglutide, Liraglutide 6 mg/mL injection, solution, listed with the FDA by Orbicular Pharmaceutical Technologies Private Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.

Orbicular Pharmaceutical Technologies Private Limited, NDC labeler code 81607. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for liraglutide?

14 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

liraglutide NDC 81607-019 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)81607-019Labeler and product segments. Claims need a package NDC.

Product NDC at billing width81607-0019Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
81607-019-01	8160700190181607001901	3 SYRINGE, PLASTIC in 1 CARTON (81607-019-01) / 3 mL in 1 SYRINGE, PLASTIC (81607-019-03)Marketed from Feb 26, 2026
81607-019-02	8160700190281607001902	5 SYRINGE, PLASTIC in 1 CARTON (81607-019-02) / 3 mL in 1 SYRINGE, PLASTIC (81607-019-03)Marketed from Feb 26, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): liraglutide
Generic name (nonproprietary): liraglutide
Active ingredients: Liraglutide — 6 mg/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Orbicular Pharmaceutical Technologies Private LimitedNDC labeler code 81607
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217234
Marketing start: Feb 26, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)
Identifiers: Product ID 81607-019_d6116799-f4f4-4bf4-a71d-8be7f105d607SPL ID d6116799-f4f4-4bf4-a71d-8be7f105d607SPL set ID d2bfc30a-8392-4255-a4d8-fa0b8d1659b2RxCUI 2735350UNII 839I73S42A
Pharmacologic class: GLP-1 Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N481607001901 followed by a unit qualifier and the quantity

Package 81607-0019-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 15, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Liraglutide injection is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. The safety and effectiveness of liraglutide injection in pediatric patients with type 2 diabetes have not been est…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 81607-019

What is NDC 81607-019?: 81607-019 is the product NDC for liraglutide, Liraglutide 6 mg/mL injection, solution, listed with the FDA by Orbicular Pharmaceutical Technologies Private Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: liraglutide.
What is the active ingredient?: Liraglutide.
Who is the labeler?: Orbicular Pharmaceutical Technologies Private Limited, NDC labeler code 81607. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for liraglutide?: 14 other product NDCs are listed under this name. See all liraglutide NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other liraglutide NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	Biocon Pharma Inc.	70377-094	70377-0094-5270377-0094-53
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Biocon Pharma Inc.	70377-095	70377-0095-5270377-0095-53
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	NorthStar Rx LLC	72603-745	72603-0745-0272603-0745-03
liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Cipla USA Inc.	69097-910	69097-0910-5569097-0910-68
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	A-S Medication Solutions	50090-8145	50090-8145-00
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Cipla USA Inc.	69097-920	69097-0920-6769097-0920-68
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Orbicular Pharmaceutical Technologies Private Limited	81607-018	81607-0018-0181607-0018-02
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	Lupin Pharmaceuticals, Inc.	70748-346	70748-0346-0270748-0346-03
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals, Inc.	0480-7250	00480-7250-46
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	Meitheal Pharmaceuticals Inc.	71288-563	71288-0563-8471288-0563-85

All 15 liraglutide NDCs

Other NDCs under ANDA 217234

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217234
Product	Strength	Form · route	Labeler	Product NDC
liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Cipla USA Inc.	69097-910